ERBB2 and non-small cell lung carcinoma: Various studies have shown that trastuzumab, alone or in combination with other chemotherapeutic agents, including cisplatin, gemcitabine, docetaxel, and paclitaxel, was effective in treating patients with HER2-mutated NSCLC, and it significantly improved the survival (Zinner et al., 2002; Mazieres et al., 2022).